PIK3CA mutations and amplifications have been reported in approximately 10% of HR-positive and HER2-negative primary BC and among patients with PIK3CA-mutated BC; those with amplified PIK3CA have worse outcomes [43]. Here, ERBB2 is linked to breast cancer.